Healthcare

Acrux (ASX:ACR) has told the market the FDA has clarified the regulatory pathway for its female testosterone spray, giving the company a clearer route toward Phase III trials for a hormone therapy aimed at Hypoactive Sexual Desire Disorder (HSDD). The update, released with the …

Actinogen Medical (ASX:ACW) has cleared another milestone on the pathway toward one of the company's most important clinical data events. The company confirmed on 18 June 2026 that an independent Data Monitoring Committee (DMC) had recommended its pivotal XanaMIA trial continue without changes after …

NeuroScientific Biopharmaceuticals (ASX:NSB) is attracting market attention during trading on 13 August 2026 as the biotechnology company moves toward a scheduled regulatory discussion with the US Food and Drug Administration. NSB shares are trading at AUD$0.064 during the session, while the company's latest announcement …

Ceryvyn Therapeutics (ASX:CYV) has entered a different phase of its listed-market history as investors assess the company's transition toward a pulmonary rare-disease program. The stock was trading at AUD$0.012 during the morning session on 13 August, reflecting rise of nearly 9%, while the company's …

Proteomics International Laboratories Ltd (ASX:PIQ) has secured a key intellectual property milestone for its PromarkerEndo diagnostic technology after receiving a notice of acceptance from IP Australia for its patent application covering the endometriosis blood test.

The central focus is Starpharma's move into targeted radiotherapy.

SomnoMed's latest update highlighted a gap between continued operational progress and softer revenue expectations.